Pharmacogenomics and systems biology of membrane transporters

Molecular Biotechnology

Volumn 29, Issue 1, 2005, Pages 75-87

  Yan, Qing ^a  

^a MEDIMMUNE   (United States)

Author keywords

Genotype; Pathway; Pharmacogenomics; Phenotype; Polymorphism; Systems biology; Transporter

Indexed keywords

ABSORPTION; CELLS; DISEASE CONTROL; DRUG PRODUCTS; TOXIC MATERIALS;

GENOTYPE; PATHWAY; PHARMACOGENOMICS; PHENOTYPE; POLYMORPHISM; SYSTEMS BIOLOGY; TRANSPORTER;

BIOLOGICAL MEMBRANES;

AMFEBUTAMONE; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; APAFANT; BESTATIN; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; CHLOROQUINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; FEXOFENADINE; FLUVOXAMINE; METHYLPHENIDATE; NUCLEOSIDE DERIVATIVE; PAROXETINE; RENIN INHIBITOR; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; STEROID; TIAGABINE;

CELL FUNCTION; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NONHUMAN; PHARMACOGENOMICS; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 26244466980     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:29:1:75     Document Type: Review

References (87)

1. Clayton, R.A., White, O., Ketchum, K.A., Venter, J.C. (1997) The first genome from the third domain of life. Nature 29, 459-462.
2. Lehninger, A.L., (1993) Principles. Biochem.. Worth Publishing, New York, pp. 1-1013.
3. Lodish, H., Baltimore, D., Berk, A., Zipursky, S.L., Matsudaira, P., Darnell, J. (1995) Mol. Cell Biol.. Scientific American Books, New York, pp. 1-1417.
4. Paulsen, I.T., Sliwinski, M.K., Saier, M.H. Jr. (1998) Microbial genome analyses: global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities. J. Mol. Biol. 277, 573-592.
5. Paulsen, I.T., Sliwinski, M.K., Nelissen, B., Goffeau, A., Saier, M.H. Jr. (1998) Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae. FEBS Lett. 430, 116-125.
6. Saier, M.H. Jr. (2000) A functional-phylogenetic classification system for transmembrane solute transporters. Microbiol. Mol. Biol. Rev. 64, 354-411.
7. Higgins, C.F. (1992) ABC transporters: from microorganisms to man. Curr. Opin. Cell Biol. 8, 67-113.
8. Martin, M.G., Lostao, M.P., Turk, E., Lam, J., Kreman, M., Wright, E.M. (1997) Compound missense mutations in the sodium/D-glucose cotransporter result in trafficking defects. Gastroenterology 112, 1206-1212.
9. Palacin, M., Bertran, J., Zorzano, A. (2000) Heteromeric amino acid transporters explain inherited aminoacidurias. Curr. Opin. Nephrol. Hypertens. 9, 547-553.
10. Sheppard, D.N., Welsh, M.J. (1999) Structure and function of the CFTR chloride channel. Physiol. Rev. 79, S23-45.
11. Hu, M., Retz, W., Baader, M., et al. (2000) Promoter polymorphism of the 5-HT transporter and Alzheimer's disease. Neurosci. Lett. 294, 63-65.
12. Le Couteur, D.G., Leighton, P.W., McCann, S.J., Pond, S. (1997) Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov. Disord. 12, 760-763.
13. Kim, J.W., Kim, D.H., Kim, S.H., and Cha, J.K. (2000) Association of the dopamine transporter gene with Parkinson's disease in Korean patients. J. Korean Med. Sci. 15, 449-451.
14. Tan, E.K., Khajavi, M., Thornby, J.I., Nagamitsu, S., Jankovic, J., and Ashizawa, T. (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55, 533-538.
15. Lee, V.H. (2000) Membrane transporters. Eur. J. Pharm. Sci. 11, S41-S50.
16. Leusch, A., Volz, A., Muller, G., et al. (2002) Altered drug disposition of the platelet activating factor antagonist apafant in mdrla knockout mice. Eur. J. Pharm. Sci. 16, 119-128.
17. Tamai, I. and Tsuji, A. (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89, 1371-1388.
18. Sugiyama, Y., Kusuhara, H., and Suzuki, H. (1999) Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Control Release. 62, 179-186.
19. Inui, K.I., Masuda, S., and Saito, H. (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58, 944-958.
20. Sadee, W., Drubbisch, V., and Amidon, G.L. (1995) Biology of membrane transport proteins. Pharm Res. 12, 1823-1837.
21. Silverman, J.A. (1999) Multidrug-resistance transporters. Pharm. Biotechnol. 12, 353-386.
22. Oh, D.M., Han, H.K., and Amidon, G.L. (1999) Drug transport and targeting. Intestinal transport. Pharm. Biotechnol. 12, 59-88.
23. Kruijtzer, C. M., Beijnen, J. H., Rosing, H., et al. (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 1, 2943-2950.
24. Iversen, L. (2000) Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol. Psychiatry. 5, 357-362.
25. Rund, D., Azar, I., and Shperling, O. (1999) A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv. Exp. Med. Biol. 457, 71-75.
26. Gerlach, J.H., Kartner, N., Bell, D.R., and Ling, V. (1986) Multidrug resistance. Cancer Surv. 5, 25-46.
27. Dalton, W.S. and Miller, T.P. (1991) Multidrug resistance, in Cancer: Principles and Practice of Oncolgy.DeVita,V.T.Jr., et al. eds., Lippincott Williams & Wilkins Publishers, Philadelphia, pp. 1-13.
28. Raymond, V. and Sattelle, D.B. (2002 ) Novel animal-health drug targets from ligand-gated chloride channels. Nat. Rev. Drug Discov. 1, 427-436.
29. Kennedy, G.C. (2000) The impact of genomics on therapeutic drug development. EXS. 89, 1-10.
30. Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491.
31. Shi, M.M., Bleavins, M.R., and de la Iglesia, F.A. (1999) Technologies for detecting genetic polymorphisms in pharmacogenomics. Mol. Diagn. 4, 343-351.
32. Sadee, W. (2002) Pharmacogenomics: the implementation phase. AAPS PharmSci 4, E5.
33. Emilien, G., Ponchon, M., Caldas, C., Isacson, O., and Maloteaux, J.M. (2000) Impact of genomics on drug discovery and clinical medicine. QJM. 93, 391-423.
34. Hess, P. and Cooper, D. (1999) Impact of pharmacogenomics on the clinical laboratory. Mol. Diagn. 4, 289-298.
35. Roses, A.D. (2000) Pharmacogenetics and pharmacogenomics in the discovery and development of medicines. Novartis Found Symp. 229, 63-66.
36. March, R. (2000) Pharmacogenomics: the genomics of drug response. Yeast 17, 16-21.
37. Vogel, F. (1959) Moderne probleme der Human-genetik. Ergeb. Inn. Med. Kinderheilkd. 12, 52-125.
38. Nebert, D.W. (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271.
39. Kitano H. (2002) Systems biology: a brief overview. Science 295, 1662-1664.
40. Winsberg, B.G. and Comings, D.E. (1999) Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry. 38, 1474-1477.
41. Assem, M., Schuetz, E.G., Leggas, M., et al. (2004) Interactions between hepatic Mrp4 and Sult2A as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279, 22250-22257.
42. Flieger, O., Engling, A., Bucala, R., Lue, H., Nickel, W., and Bernhagen, J. (2003) Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett. 11, 78-86.
43. Hoffmeyer, S., Burk, O., von Richter, O., et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478.
44. Lesch, K.P., Bengel, D., Heils, A., et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531.
45. Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., and Catalano, M. (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry. 3, 508-511.
46. Kim, D.K., Lim, S.W., Lee, S., et al. (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 11, 215-219.
47. Pollock, B.G., Ferrell, R.E., Mulsant, B.H., et al. (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590.
48. Zanardi, R., Benedetti, F., Di Bella, D., Catalano, M., and Smeraldi, E. (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 20, 105-107.
49. Camilleri, M., Atanasova, E., Carlson, P.J., et al. (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123, 425-432.
50. Anderson, M.P., Berger, H.A., Rich, D.P., Gregory, R.J., Smith, A.E., and Welsh, M.J. (1991) Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 67, 775-784.
51. Berger, H.A., Anderson, M.P., Gregory, R.J., et al. (1991) Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. J. Clin. Invest. 88, 1422-1431.
52. Lichtermann, D., Hranilovic, D., Trixler, M., et al. (2000) Support for allelic association of a polymorphic site in the promoter region of the serotonin transporter gene with risk for alcohol dependence. Am. J. Psychiatry. 157, 2045-2047.
53. Hipfner, D.R., Deeley, R.G., and Cole, S.P. (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359-376.
54. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (1999) The multidrug resistance protein family. Biochim. Biophys. Acta 1461, 347-357.
55. Konig, J., Nies, A.T., Cui, Y., Leier, I., and Keppler, D. (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394.
56. Bejanin, S., Cervini, R., Mallet, J., and Berrard, S. (1994) A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem. 269, 21944-21947.
57. Erickson, J.D., Varoqui, H., Schafer, M.K., et al. (1994) Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269, 21929-21932.
58. Protein Data Bank (PDB): http://www.rcsb.org/pdb/
59. Human Membrane Transporter Database: http://lab.digibench.net/transporter
60. KEGG PATHWAY Database: http:/www.genome.ad.jp/kegg/pathway.html
61. Lewis, R.A., Shroyer, N.F., Singh, N., et al. (1999) Genotype/Phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease. Am. J. Hum. Genet. 64, 422-434.
62. Tokuhiro, S., Yamada, R., Chang, X., et al. (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 35, 341-348.
63. Nebert, D.W. (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 56, 247-258.
64. Dirckx, C., Donati, M.B., and Iacoviello, L. (2000) Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologists? Ital. Heart J. 1, 662-666.
65. Lerman, C., Shields, P.G., Wileyto, E.P., et al. (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22, 541-548.
66. Sadee, W. (1998) Genomics and drugs: finding the optimal drug for the right patient. Pharm. Res. 15, 959-963.
67. Nebert, D.W., Jorge-Nebert, L., and Vesell, E.S. (2003) Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am. J. Pharmacogenomics. 3, 361-370.
68. Brooks-Wilson, A., Marcil, M., Clee, S. M., et al. (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 22, 336-345.
69. Bodzioch, M., Orso, E., Klucken, J., et al. (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347-351.
70. Allikmets, R., Shroyer, N. F., Singh, N., et al. (1997) Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 277, 1805-1807.
71. Rivera, A., White, K., Stohr, H., et al. (2000) A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am. J. Hum. Genet. 67, 800-813.
72. Dixon, P. H., Weerasekera, N., Linton, K. J., et al. (2000) Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Molec. Genet. 9, 1209-1217.
73. Cartier, N., Sarde, C.-O., Douar, A.-M., Mosser, J., Mandel, J.-L., and Aubourg, P. (1993) Abnormal messenger RNA expression and a missense mutation in patients with X-linked adrenoleukodystrophy. Hum. Molec. Genet. 2, 1949-1951.
74. Krasemann, E. W., Meier, V., Korenke, G. C., Hunneman, D. H., and Hanefeld, F. (1996) Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. Hum. Genet. 97, 194-197.
75. Kaler, S. G., Gallo, L. K., Proud, V. K., et al. (1994) Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nature Genet. 8, 195-202.
76. Figus, A., Angius, A., Loudianos, G., et al. (1995) Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations. Am. J. Hum. Genet. 57, 1318-1324.
77. Kim, E. K., Yoo, O. J., Song, K. Y., et al. (1998) Identification of three novel mutations and a high frequency of the arg778-to-leu mutation in Korean patients with Wilson disease. Hum. Mutat. 11, 275-278.
78. Jarolim, P., Palek, J., Rubin, H. L., Prchal, J. T., Korsgren, C., and Cohen, C. M. (1991) Band 3 Tuscaloosa: pro327-to-arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2. (Abstract) Blood 78 (suppl.), 252a.
79. Wang, Y., Korman, S. H., Ye, J., et al. (2001) Phenotype and genotype variation in primary carnitine deficiency. Genet. Med. 3, 387-392.
80. Van Hauwe, P., Everett, L. A., Coucke, P., et al. (1998) Two frequent missense mutations in Pendred syndrome. Hum. Molec. Genet. 7, 1099-1104.
81. Usami, S., Abe, S., Weston, M. D., Shinkawa, H., Van Camp, G., and Kimberling, W. J. (1999) Non-syndromic hearing loss associated with enlarged vestibular aqueduct is caused by PDS mutations. Hum. Genet. 104, 188-192.
82. Colonna, M., Bresnahan, M., Bahram, S., Strominger, J. L., and Spies, T. (1992) Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Nat. Acad. Sci. USA 89, 3932-3936.
83. Mockenhaupt, F.P., Eggelte, T.A., Till, H., and Bienzle, U. (2001) Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana. Trop. Med. Int. Health 6, 749-755.
84. Basco, L.K. and Ringwald, P. (2001) Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J. Infect. Dis. 183, 1828-1831.
85. Kim, R.B., Leake, B.F., Choo, E.F., et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199.
86. Tirana, R.G., Leake, B.F., Merino, G., and Kim, R.B. (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675.
87. Winsberg, B.G. and Comings, D.E. (1999) Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry 38, 1474-1477.